Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance

Neurocrine Biosciences IncTrade
Royal Caribbean Cruises LtdTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Royal Caribbean Cruises Ltd — how do they compare? Neurocrine Biosciences Inc trades at $159.01 (market cap $16.46B), while Royal Caribbean Cruises Ltd trades at $307.81 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 5× Neurocrine Biosciences Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.63% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXRCL
Market Cap
$16.46B$82.15B
Sector
HealthConsumer Cyclical
52-Week High
$185.50$365.84
52-Week Low
$123.10$246.71
Enterprise Value
$16.48B$104.79B
Dividend Yield
1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Royal Caribbean Cruises Ltd

Royal Caribbean (RCL) trades at $308, down 3.75% today, as strong earnings growth and bullish technical signals are tempered by geopolitical concerns affecting European demand. The company reported Q2 2026 EPS of $4.21, beating estimates, and raised full-year guidance, with revenue reaching $17.93B in 2025. Technical analysis shows a bullish trend with support at $305 and resistance at $314, while fundamentals highlight robust profitability with a 23.54% net margin and 45.33% ROE.

RCL presents a compelling growth story with record bookings and fleet expansion through 2028, though risks include high debt levels, capital-intensive spending, and geopolitical volatility. Analyst consensus is bullish with a $343 price target, but investors should weigh strong cash flow generation against ongoing investment requirements and market sensitivity to economic cycles.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Royal Caribbean Cruises Ltd

Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.

Read more on RCL